PharmAbs clusters unique expertise in antibody generation, selection, production, characterisation, humanisation and tailor-made engineering combined with proven excellence in biopharmaceutical and diagnostic development and with customized patent strategies for biotechnology derived products (antibodies).

► Immunization of rabbits(generation of polyclonal antibodies)
► Generation of monoclonal antibodies (protein and DNA immunization)
► Derivatization of monoclonal antibodies (Fab, scFv, diabodies,...)
► Characterization of biochemical properties
► Development of diagnostica (ELISA,...)
► Human monoclonal antibody development and production
► Bio-molecular modeling (i.e. humanisation of proteins)

In addition, it is our mission to continuously develop novel, innovative antibody technologies. Currently, we are engaged in the following antibody technology projects:

► Development of our own proprietary fully human monoclonal antibody platform

►Evaluation of antibody-coated paramagnetic micro-/nanobeads for specific capturing of targets in complex samples

►Generation of small and stable antibody formats

►PharmAbs initiated a collaboration with the Finnish Biotech company FitBiotech to evaluate the potential of therapeutic antibody gene transfer.

All existing and novel antibody technologies will be easily accessible for academic groups and the industry.